ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Vical To Present Phase 1 Data For Vaxfectin(R)-Formulated Pandemic Influenza DNA Vaccines
Vical Incorporated
(Nasdaq: VICL) announced the scheduled presentation of preliminary
human safety and immunogenicity data from a Phase 1 trial of the company's
Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines on Thursday,
July 17, at the IBC Life Sciences Next Generation Vaccines conference
(National Harbor, MD - July 17-18).
Vical's Vice President of Vaccine Research, Larry R. Smith, Ph.D., will
present preliminary safety and immunogenicity results from this first human
trial of vaccines formulated with the company's patented Vaxfectin(R)
adjuvant. Results from this trial will drive the next steps in the
company's H5N1 pandemic influenza vaccine program and could expand
collaborative opportunities for both the Vaxfectin(R) adjuvant and the
Vical DNA vaccine technology.
The double-blind, placebo-controlled, dose-escalation trial was
conducted in approximately 100 healthy volunteers age 18 to 45 at three
U.S. clinical sites. The trial was designed to assess safety and
immunogenicity following intramuscular vaccination with needle and syringe
or with the Biojector(R) 2000 needle-free injection system in different
cohorts, and to evaluate monovalent and trivalent Vaxfectin(R)-formulated
DNA vaccines at various doses.
Vical's monovalent vaccine contains a plasmid (a closed loop of DNA)
encoding the hemagglutinin (HA) surface protein from the H5N1 influenza
virus strain, A/Vietnam/1203/04. It is designed primarily to elicit
antibody responses against the H5 protein, but could elicit T-cell
responses against H5 as well. Vical's trivalent vaccine contains the H5
plasmid plus separate plasmids encoding consensus sequences of two
highly-conserved influenza virus proteins: nucleoprotein (NP) and ion
channel protein (M2). The trivalent vaccine is designed to elicit a
combination of T-cell and antibody responses against all three proteins.
Both vaccines are formulated with the company's Vaxfectin(R) adjuvant,
which has demonstrated effectiveness with a variety of DNA vaccines in
multiple animal models as well as dose-sparing and immune-enhancing ability
in animals with a conventional seasonal influenza vaccine.
About Vical
Vical researches and develops biopharmaceutical products based on its
patented DNA delivery technologies for the prevention and treatment of
serious or life-threatening diseases. Potential applications of the
company's DNA delivery technology include DNA vaccines for infectious
diseases or cancer, in which the expressed protein is an immunogen; cancer
immunotherapeutics, in which the expressed protein is an immune system
stimulant; and cardiovascular therapies, in which the expressed protein is
an angiogenic growth factor. The company is developing certain infectious
disease vaccines and cancer therapeutics internally. In addition, the
company collaborates with major pharmaceutical companies and biotechnology
companies that give it access to complementary technologies or greater
resources. These strategic partnerships provide the company with mutually
beneficial opportunities to expand its product pipeline and address
significant unmet medical needs. Additional information on Vical is
available at http://www.vical.com.
This press release contains forward-looking statements subject to risks
and uncertainties that could cause actual results to differ materially from
those projected. Forward-looking statements include statements about the
next steps in the company's pandemic influenza vaccine program, the effect
of the preliminary Phase 1 clinical trial results on the company's
collaborative opportunities, and the design and potential benefits of the
company's pandemic influenza vaccines. Risks and uncertainties include
whether results from the Phase 1 trial will be favorable; whether Vical or
others will continue development of the pandemic influenza vaccines or any
other product candidates; whether results from the Phase 1 trial will
determine next steps in the company's pandemic influenza vaccine program or
expand collaborative opportunities for the Vaxfectin(R) adjuvant or the
Vical DNA vaccine technology; whether any product candidates will be shown
to be safe and efficacious in clinical trials; the timing of clinical
trials; whether Vical or its collaborative partners will seek or gain
approval to market any product candidates; the dependence of the company on
its collaborative partners; and additional risks set forth in the company's
filings with the Securities and Exchange Commission. These forward-looking
statements represent the company's judgment as of the date of this release.
The company disclaims, however, any intent or obligation to update these
forward-looking statements.
Vical Incorporated
http://www.vical.com
Vical sã prezinte Faza 1 de date pentru Vaxfectin (R)-formulate gripa pandemicã ADN Vaccinuri - Vical To Present Phase 1 Data For Vaxfectin(R)-Formulated Pandemic Influenza DNA Vaccines - articole medicale engleza - startsanatate